Prøve GULL - Gratis
The ESRD crisis in Singapore
BioSpectrum Asia
|December 2020
In Singapore – where the crude incidence rate of late-stage chronic kidney disease has been rising – there are more people in the country, who must be especially concerned about maintaining social distancing. This is a particular conundrum for ESRD patients, who need to visit dialysis centres for treatment.
-

The COVID-19 pandemic is an unprecedented global emergency that – at the time of writing – has infected over 40 million people worldwide and claimed the lives of over a million people. Even though primarily regarded as a respiratory virus, more evidence is emerging that COVID-19 can affect multiple organs in the body, especially the immune and haematologic systems. This makes it even more dangerous to patients suffering from chronic diseases, particularly end-stage renal disease (ESRD) sufferers, who can be considered immunocompromised and may have multiple comorbidities.
In Singapore – where the crude incidence rate of late-stage chronic kidney disease has been rising – there are more people in the country, who must be especially concerned about maintaining social distancing. This is a particular conundrum for ESRD patients, who need to visit dialysis centres for treatment.
Dangerous to ESRD patients
When transmitted, the COVID-19 coronavirus enters the body through the respiratory system and begins to attack the lungs. From there, if not treated, it can attack other organs such as the kidneys, evidenced by a US study that found nearly a third of COVID-19 patients in intensive care developed acute kidney injury (AKI), with 15 per cent of those requiring dialysis.
Also, existing AKI sufferers who contracted COVID-19 were reported as being five times more likely to die from the virus – placing ESRD patients firmly in the ‘at-risk group’ as AKI frequently leads to ESRD. It therefore comes as little surprise that dialysis machines are as high in demand at hospitals as ventilator machines. This is because kidney failure incidences and AKI in COVID-19 patients are soaring – with an estimated 20 to 40 per cent of ICU patients in the US needing emergency dialysis.
Denne historien er fra December 2020-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size